Loading…

IBEX LtdIBEXCompetitor analysis, valuation and peers

United States · USD·Industrials›Miscellaneous Commercial Services
Momentum leader 96
Mkt cap
$661M
US dollars, full cap
Free float
80%
of shares outstanding
$/day
$4.97M
20-day average traded
Fwd P/E
13.1×
forward earnings
ROIC−WACC
+13.9 pp
WACC 8.3%
Hurdle
-7 pp
Req g minus delivered
Next earnings
103 days
17 Feb 2027
Close · USD$49.52
1D+15.2%
1W+10.7%
1M+11.5%
3M+33.8%
6M+53.2%
YTD+29.7%
1Y+32.3%
ATR %3.9%
Beta0.62
52w lowhigh0.7% off high

What IBEX does

Employees: 35,000

IBEX at a glance

Size IBEX (IBEX) is a United States Industrials company (Miscellaneous Commercial Services) with a market value of $661M, the 2527th largest of 3,117 United States companies the cockpit tracks. Shares closed at $49.52 on 6 Nov 2026.

Performance Over six months the shares gained 53.2%, against -12.1% for the median peer and -1.1% for the United States market (cap-weighted) — 2nd highest of 21 in its peer set.

Growth Revenue grew 15.4% over the last twelve months (peer median +11.7%); the operating margin is 8.7% (peer median 7.4%).

Valuation It trades at 13.1× forward earnings against a peer median of 13.6× (7th cheapest of 13).

Price implies For today's price to make sense, revenue must grow about 0% a year for seven years (Req g). Recent delivered growth is +8%, so the hurdle is -7 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 13.9 points above its cost of capital (8.3% WACC).

Short interest Short interest is 1.3% of the free float (15 Oct 2026).

Next results Next results expected around 17 Feb 2027 (exchange calendar; dates can move).

Relative performance

10012515011 May 202611 Aug 20266 Nov 2026IBEX 152Peer median 89
Six months, rebased to 100: IBEX against the median of its 20 peers (local-currency closes).

IBEX financials

Reported figures in USD; fiscal year ends 2026-06-30. TTM = trailing twelve months.
TTMFY2026FY2025FY2024FY2023
Revenue$644M$644M$558M$509M$523M
Revenue growth—+15%+10%-3%—
Gross profit$172M$171M$155M$133M$130M
EBITDA$76.0M$76.9M$65.9M$60.7M$75.1M
Net income$46.3M$46.3M$36.9M$33.7M$31.6M
Free cash flow$31.2M$31.2M$27.3M$27.0M$22.9M
Capital expenditure$27.8M$27.8M$18.4M$8.86M$19.0M
Total debt$62.4M$62.4M$69.8M$67.0M$78.9M

Quarterly statements and history in the cockpit →

IBEX competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%-25%0%+25%+50%-20%0%301365301528688079300149RWSINTRUM30079708396183603778FRAMERY6884806027CGY22913013986030072192301468JSGIBEX6-month return →1-month return →
Up and to the right = strong over both horizons. IBEX is the large dot.

Fundamentals: revenue growth against valuation

0%+10%+20%+30%+40%0×20×40×60×RWS30079708396183FRAMERY6884806027CGY22912192301468IBEXRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. IBEX is the large dot.

Capital: growth delivered against growth the price implies

0%+20%+40%0%20%40%301365301528300149RWSINTRUM3007976183FRAMERY6884806027CGY22912192JSGIBEXGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. IBEX is the large dot.

IBEX competitors and peer comparison

How IBEX compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

IBEX against its 20 peers (data as of 6 Nov 2026)
MeasureIBEXPeer medianRank in peer set
1-month return+11.5%-7.1%2nd highest of 21
6-month return+53.2%-12.1%2nd highest of 21
Distance from 52-week high-0.7%-41.9%highest of 21
Revenue growth (TTM)+15.4%+11.7%10th highest of 21
Operating margin8.7%7.4%10th highest of 21
Forward P/E13.1×13.6×7th cheapest of 13
Growth the price implies (Req g, 7 yrs)0.3%12.4%5th least demanding of 15
Growth delivered (Del g)+7.7%+13.8%5th lowest of 15
Hurdle (Req g minus delivered)-7.5 pp-4.6 pp6th least demanding of 15
ROIC minus cost of capital+13.9 pp-2.6 pp3rd highest of 21
EV / EBITDA9.1×8.0×6th most expensive of 12
Net debt / EBITDA0.4×1.2×4th least indebted of 12

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
IBEX IBEXUnited States$661M+53%+15%9%13.1×0.3%+7.7%
Matrix Design 301365.SZChina$660M-31%+9%4%n/a29.3%+3.6%
Guangzhou Doppler Electronic Technologies 301528.SZChina$663M-5%+35%22%n/a42.2%+11.8%
Hangzhou MDK Opto Electronic 688079.SSChina$666M-28%+30%-26%n/an/an/a
ChemPartner PharmaTech 300149.SZChina$645M-14%+18%2%n/a25.6%-5.2%
RWS RWS.LUnited Kingdom$677M+46%-1%4%10.3×11.5%+14.2%
Intrum INTRUM.STSweden$645M-53%-4%28%n/a-8.9%+0.2%
NCS Testing Technology 300797.SZChina$678M-26%+15%7%25.1×22.3%+15.0%
China Education 0839.HKHong Kong$680M-4%+9%32%3.0×n/an/a
BELLSYSTEM24 6183.TJapan$637M-10%+1%8%11.3×-5.7%+1.4%
Grand Sunergy Tech 603778.SSChina$686M-73%-54%-98%n/an/an/a
Framery FRAMERY.HEFinland$632M0%+37%20%14.7×5.9%+13.4%
Science Environmental Protection 688480.SSChina$694M-51%+37%10%29.7×28.2%+28.2%
Bengo4.com 6027.TJapan$695M+94%+19%14%51.8×18.7%+25.1%
Calian CGY.TOCanada$699M+22%+16%6%18.7×13.4%+12.4%
LEPU ScienTech Medical Technology (Shanghai) 2291.HKHong Kong$624M+25%-4%42%11.8×-8.4%+28.0%
Ningbo Sinyuan ZM Technology 301398.SZChina$700M-5%+42%-18%n/an/an/a
Danyang Syngen Intelligent Technology 603007.SSChina$702M-25%+929%-34%n/an/an/a
Medlive Technology 2192.HKHong Kong$621M-25%+6%29%12.6×-0.3%+23.8%
Pourin Special Welding Technology 301468.SZChina$621M-40%-4%5%66.1×n/an/a
Johnson Service JSG.LUnited Kingdom$704M+10%+2%11%11.0×8.3%+18.4%

Questions

Which companies are IBEX's closest peers?
The cockpit's peer set: Matrix Design (301365.SZ), Guangzhou Doppler Electronic Technologies (301528.SZ), Hangzhou MDK Opto Electronic (688079.SS), ChemPartner PharmaTech (300149.SZ), RWS (RWS.L), Intrum (INTRUM.ST), NCS Testing Technology (300797.SZ), China Education (0839.HK).
Is IBEX expensive compared with its peers?
On forward p/e it trades at 13.1× against a peer median of 13.6×, 7th cheapest of 13 in its peer set. For today's price to make sense, revenue must grow about 0% a year for seven years (Req g). Recent delivered growth is +8%, so the hurdle is -7 pp: the price already allows for a slowdown.
How has IBEX stock performed?
Over six months to 6 Nov 2026 the shares returned +53.2% against -12.1% for the median peer; over one year +32.3%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.